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Evidence suggests oxidative and electrophilic stress as a major factor contributing 
to the neuronal cell death in neurodegenerative disorders, especially Parkinson's disease 
(PD). Early depletion in the levels of thiol antioxidant glutathione (GSH), which may 
lead to generation of reactive oxygen species, is an important biochemical feature of PD. 
Many toxins including 4-hydroxynonenal, acrolein, and peroxynitrite are known to cause 
oxidative stress and contribute to the development of neurodegenerative disorders. This 
study was undertaken to determine whether CDDO-Im (2-cyano-3,12 dioxooleana-1,9 
dien-28-oyl imidazoline), a novel triterpenoid compound, could increase endogenous 
antioxidant defenses protecting against the above neurotoxicant-mediated cytotoxicity in 
retinoic acid-induced differentiated SH-SY5Y cells.  Retinoic acid-induced differentiated 
human neuroblastoma SH-SY5Y cells are known to possess properties of mature neurons 
and thus have been a widely used in vitro model for the study of neurotoxicity and 
neuroprotection. In this study, we showed that incubation of retinoic acid-induced 
differentiation of human neuroblastoma SH-SY5Y cells with nanomolar concentrations 
of CDDO-Im (1- 400 nM) for 24 h resulted in a significant increase in the levels of 
reduced glutathione (GSH) and NAD(P)H:quinone oxidoreductase 1 (NQO1), two 
critical cellular defenses in detoxification of reactive oxygen species and electrophilic 
quinone molecules.  Pretreatment of the cells with CDDO-Im was found to afford 
remarkable protection against the neurocytotoxicity elicited by 4-hydroxynonenal, 3-
 
 
morpholinosynonimine hydrochloride, xanthine oxidase/xanthine, hydrogen peroxide as 
well as the environmental neurotoxin acrolein. Acrolein is a ubiquitous unsaturated 
aldehyde product occurring in the combustion of organic matter including exhausts and 
pollutants and has been implicated in the pathogenesis of various neurological disorders 
including Parkinson’s disease where acrolein-protein adducts have been observed in post 
mortem studies. To further determine the role of cellular GSH in CDDO-Im-mediated 
protection against the acrolein induced cytotoxicity, buthionine sulfoximine (BSO) was 
used to inhibit cellular GSH biosynthesis. BSO at 25µM dramatically depleted GSH and 
significantly potentiated acrolein-induced cytotoxicity. Pretreatment of RA-differentiated 
SH-SY5Y cells with both 25µM BSO and 100nM CDDO-Im was found to prevent the 
CDDO-Im mediated GSH induction and partially reverse the cytoprotective effects of 
CDDO-Im treatment on acrolein-induced toxicity.   
Taken together, this study demonstrates for the first time that CDDO-Im potently 
induces the cellular GSH system and NQO1 in RA-differentiated human neuroblastoma 
SH-SY5Y cells, which is accompanied by dramatically increased resistance of these cells 
to the damage induced by various neurotoxicants. In addition, we show that the CDDO-
Im-mediated up regulation of GSH is a predominant mechanism against acrolein-induced 
neurotoxicity. The results of this study may have important implications for the 
development of novel neuroprotective strategies.
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CHAPTER I 
 
BACKGROUND 
 
 
Oxidative Stress 
 The term oxidative stress encompasses many types of cellular damage caused by 
reactive oxygen species (ROS). ROS include all oxygen-free radicals that can be 
generated exogenously through radiation, metal-catalyzed reactions, exposure to 
atmospheric pollutants, as well as produced endogenously by mitochondria-controlled 
electron transport chain reactions and other metabolic reactions[1]. Mitochondria are 
known to produce superoxide (02-) which degrades into hydrogen peroxide (H202) as part 
of its electron transport chain and ATP synthesis. H202 is not reactive itself but leads to 
the formation of other more reactive ROS including peroxinitrite (ONOO-), and the 
hydroxyl ion (OH-). Exogenous xenobiotics can both directly and indirectly generate 
ROS. Acrolein is an example of the latter [2-4]. 
Acrolein is an environmental toxin found in many pesticide products and as a 
product in the combustion of organic matter.[5]. As a reactive aldehyde, acrolein, has 
been found to readily damage lipids, making fatty acid rich nerve cell types primary 
targets [6]. Recent studies show that the resulting oxidative damage leads to decreased 
cell proliferation and increased apoptosis [7, 8]. Acrolein can also be formed inside the 
cell as a product of lipid peroxidation by other forms of ROS [4]. Neuronal cell exposure 
to acrolein and other reactive oxygen species (ROS) generating compounds and the 
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subsequent cellular damage are found to be associated with the progression of 
Parkinson’s disease (PD) as well as other neurodegenerative disorders [9, 10]. Elevated 
concentrations of acrolein, up to 40µM, have been found in the brain tissue of PD 
patients and are considered a specific marker for lipid peroxidation damage [7, 11].  
 
Pathological Effect of Oxidative Stress on the Brain 
The brain and neuronal cell types remain some of the most vulnerable cell types 
to oxidative stressors. Neurons have been shown to perform cellular respiration at a 
higher rate than other cell types; 20% of the oxygen consumed by the human body is 
allocated to brain function. More cellular respiration causes more oxygen turn over and 
increases levels of oxidative stress [12, 13]. The brain’s vulnerability also stems from the 
fact that the cells contain a large amount of polyunsaturated fatty acids which are primary 
targets for ROS and exogenous toxins [6].  Cellular protection against oxidative damage 
is associated with antioxidant production; neuronal cells consequently have a limited 
capacity for antioxidant up regulation and are susceptible to damage [14]. Thus, 
importance must be placed on the regulation of the antioxidant defense system in order to 
reduce the neurodegenerative effects of oxidative damage and prevent disorders such as 
Parkinson’s disease. 
 
Parkinson’s Disease (PD) 
Parkinson’s disease (PD) is a prolific neurodegenerative disorder with increasing 
incidence across the world [15, 16]. The pathogenesis of PD has been related to the 
degeneration of dopaminergic neuron cells by oxidative stress and can be exacerbated by 
3 
 
exogenous environmental toxins [17, 18]. These environmental toxins, along with ROS, 
have been implicated in the alteration of essential cellular components leading to cellular 
dysfunction and ultimately apoptosis of the cells in neurodegenerative disorders [18]. In 
PD, oxidative damage has been found to specifically target nigrostriatal neurons 
associated with fine motor control. As previously mentioned, neuronal cell vulnerability 
stems from the cell’s large amount of polyunsaturated fatty acids which have been shown 
to be primary targets for reactive oxygen species and exogenous toxins [6]. Specifically, 
unsaturated aldehydes and markers of lipid peroxidation damage have been found in 
elevated concentrations in brain tissue of patients with neurodegenerative disorders [19]. 
Due to the environmental factor involved in the pathogenesis of PD, development of 
novel preventative treatment options has become increasingly important. 
 
Antioxidant Defenses 
The cellular antioxidant defense system includes endogenous enzymes as well as 
exogenous compounds which help promote protection against toxic effects. Glutathione 
(GSH) is important for cellular defense against ROS and has been found at high 
concentrations in stressed cells.  Increased intracellular concentrations of GSH and its 
enzymatic derivatives, glutathione-S-transferase (GST), glutathione reductase (GR), and 
glutathione peroxidase (GPx), result in the detoxification of many types of ROS[20]. 
GSH and GST have also been implicated in neuronal cell protection against 
environmental toxins such as acrolein[21]. In addition to endogenous compounds, 
exogenous antioxidant promoting substances have been shown to increase cellular 
antioxidant levels, including GSH.  
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Recently, many studies focus on the use of exogenous antioxidant compounds to 
prevent oxidative damage to the brain. These treatment options, however, have been 
shown to be limited in their lack of long term effectiveness and sometimes lead to 
potentially dangerous side effects making them poor choices for therapeutic 
nutraceuticals[22-26].  Synthetic indirect protective compounds including triterpenoids, 
however, have been shown to increase neuron robustness and are associated with 
increased antioxidant regulation [27]. 
 
Triterpenoids and CDDO-Im 
Triterpenoids are steroid-like compounds derived from plant extracts which have 
been shown to have numerous protective/therapeutic effects on various cell types[28]. 2-
Cyano-3,12-dixooleana-1,9-dien-28-imidazolide (CDDO-Im) (Figure 1) is a synthetic 
triterpenoid designed to be more potent and to effect mammalian signaling pathways 
associated with detoxification and apoptosis [29, 30].  
Accordingly, plant-derived triterpenoids, including oleanolic acid CDDO, have 
shown to increase cell viability and are associated with increased antioxidant regulation 
[27]. Recently, CDDO has been used as a cancer prevention treatment as well as an anti-
inflammatory therapeutic and is currently in clinical trials [31-34]. Despite the recent 
studies and successes in the therapeutic use of CDDO in human disease, there are limited 
studies involving its neuroprotective capabilities. 
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Proposed Study 
In this study we proposed to test the potential neuroprotective capabilities of the 
triterpenoid CDDO-Im against various oxidative and electrophilic species in human SH-
SY5Y neuroblastoma cells. The hypothesis we put forth was that treatment with 
nanomolar levels of CDDO-Im could upregulate endogenous cellular antioxidant 
enzymes in SH-SY5Y cells, which might then lead to cytoprotective effects against 
oxidative and electrophilic damage.  Accordingly, the study aims were designed to: first, 
study the induction of endogenous antioxidant defenses by CDDO-Im in human 
neuroblastoma SH-SY5Y cells and the protective effects of CDDO-Im pretreatment in 
the cells when exposed to various types of oxidative and electrophilic species. Secondly, 
we aimed to determine the mechanistic role of GSH in CDDO-Im-mediated protection 
against acrolein-induced neurocytotoxicity. 
 
 
Figure 1. Chemical structure of CDDO-Im. Chemical structure of 2-Cyano-3,12-
dixooleana-1,9-dien-28-imidazolide (CDDO-Im) supplied by Toronto Research 
Chemicals Inc. 
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CHAPTER II 
INDUCTIONS OF ENDOGENOUS ANTIOXIDATIVE ENZYMES BY CDDO-IM 
AND ITS PROTECTIVE EFFECTS ON VARIOUS OXIDATIVE AND 
ELECTROPHILIC CELL INJURIES IN SH-SY5Y CELLS 
 
Introduction 
Parkinson’s disease (PD) is a prolific neurodegenerative disorder with increasing 
incidence across North America and Europe [15, 16]. The debilitating disorder has been 
related to the degeneration of dopaminergic neuron cells by oxidative stress and can be 
exacerbated by exogenous environmental toxins [17, 18]. Oxidative stress is implicated 
in the alteration of essential cellular components such as nucleic acids, proteins, and 
lipids leading to cellular dysfunction and ultimately apoptosis of the cells in  
neurodegenerative disorders [18]. In PD, oxidative damage of neuronal cells, specifically 
nigrostriatal neurons, has been found as a primary cause leading to the onset of the 
disease. Neuronal cell vulnerability stems from the cell’s large amount of polyunsaturated 
fatty acids which have been shown to be primary targets for reactive oxygen species and 
exogenous toxins [6]. Specifically, unsaturated aldehydes such as 4-hydroxy-2-noneal 
(HNE), which causes lipid peroxidation damage, have been found in elevated 
concentrations in brain tissue of patients with neurodegenerative disorders [19]. Neuron 
cell vulnerability is highly dependent on the amount of oxidative damage incurred
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overtime. Thus, it is increasingly important to find applicable treatment options for 
neurodegenerative disorders such as PD.  
Numerous studies focus on the use of exogenous antioxidant compounds to 
prevent oxidative damage to the brain; however, there are several factors which raise 
questions to their effectiveness. Many treatment options which have demonstrated the 
protective effects such as vitamin C and Cu/Zn-superoxide dismutase, are also 
susceptible to limited bioavailability, inefficient permeability, and potentially more 
damaging metabolic reactions[26]. All of which make them poor choices as therapeutic 
nutraceuticals[22-26]. An alternative strategy for reducing oxidative damage is to 
increase the naturally occurring cellular defenses which suppress ROS generation. 
Increased intracellular concentrations of the tripeptide antioxidant GSH and its enzymatic 
derivatives, glutathione-S-transferase (GST), glutathione reductase (GR), and glutathione 
peroxidase (GPx) are known to contribute to the detoxification of many types of 
ROS[20]. GSH and GST have also been implicated in neuronal cell protection against 
environmental toxins such as acrolein[21].  Similarly, the upregulation of natural phase II 
enzymes such as NQO1 has been shown to contribute to the detoxification of ROS in 
neuronal cell types [35]. For these reasons it is of great interest to develop therapeutic 
strategies via increase in the natural endogenous cellular defense mechanisms including 
GSH and NQO1 to reduce oxidative damage mediated by a bioactive 
nutraceutical/pharmacological agent  
Accordingly, plant-derived triterpenoids, including oleanolic acid and synthetic 
triterpenoid CDDO, have shown to increase cell viability and are associated with 
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increased antioxidant regulation [27]. Triterpenoids are steroid like compounds which 
occur naturally in plant extracts used for medicinal purposes[28]. Recently, CDDO has 
been used as a cancer prevention treatment as well as an anti-inflammatory therapeutic 
and is currently in clinical trials [31-34]. Despite the recent studies and successes in the 
therapeutic use of CDDO in human disease there are limited studies involving its 
neuroprotective capabilities.  One exception is the work of Yang et al who has shown that 
2-cyano-N-methyl-3,12-dioxooleana-1,9(11)-dien-28 amide (CDDO-MA) is capable of 
activating transcription factors associated with antioxidant defense and increase some 
intracellular antioxidant compounds in SH-SY5Y cells and mouse models [36]. These 
results provide an observation of the potential use of CDDO in neuronal protection; 
however, a few issues are not addressed. The SH-SY5Y cell model is not differentiated to 
more closely resemble human dopaminergic neuronal cells [37]. Also, cytoprotection is 
not addressed when exposed to various types of oxidative stress. Finally, Yang et al 
utilize high concentrations of CDDO, as low as 500nM, in SH-SY5Y cells to observe 
increased antioxidant defenses. Overall, the lack of recent studies limits the conclusions 
that can be drawn from the use of CDDO in human nerve cells and deserves further 
study. 
In our study, we used human SH-SY5Y cells differentiated with retinoic acid 
(RA) as an in vitro system to investigate the coordinated induction of endogenous 
antioxidant defenses by 2-cyano-3,12 dioxooleana-1,9 dien-28-oyl imidazoline (CDDO-
Im) (Figure 1), as well as its potential protective capabilities against oxidative damage 
induced by various of neurotoxins. RA-differentiated SH-SY5Y cells have been shown to 
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share similar characteristics of dopaminergic neurons and are a good in vitro model for 
studying neurotoxicology and neuroprotection (Figure 2) [38, 39]. This study 
demonstrates for the first time that CDDO-Im as low as 1 nM potently induces the 
cellular GSH and the phase 2 enzyme NQO1 in RA-differentiated SH-SY5Y cells. 
Furthermore, the CDDO-Im-mediated coordinated upregulation of cellular defenses is 
accompanied by remarkably increased resistance of the cells to oxidative and 
electrophilic stress. 
 
 
 
Figure 2. SH-SY5Y cell morphology change when treated with Retinoic Acid (RA). 
Panel A depicts undifferentiated SH-SY5Y cells grown in 10% FBS DMEM medium. 
Panel B depicts differentiation of SH-SY5Y cells by all-trans-retinoic acid (RA) 
treatment (10 µM) for 5 days. 
 
Materials and Methods 
 
Chemicals and Materials 
Dulbecco’s modified Eagle’s medium (DMEM), penicillin streptomycin, and fetal 
bovine serum (FBS) were obtained from Gibco-Invitrogen (Carlsbad, CA). CDDO-Im [2-
Cyano-3,12-dixooleana-1,9-dien-28-imidazolide] was obtained from Toronto Research 
A: Control SH-SY5Y Cells B: RA differentiated
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Chemicals Inc. ( Toronto, Canada). Acrolein, Retinoic Acid (RA), 3-
morpholinosynonimine hydrochloride (SIN-1), 4-hydroxy-2-nonenal (HNE), Xanthine 
Oxidase, Xanthine Sodium Salt, GSH, 1-chloro-2,4dinitrobenzene (CDNB), o-
phtalaldehyde, 3-[4,5-dimethylthiazol-2yl]-2,5-diphenyltertrazolium bromide (MTT) 
were from Sigma Chemical (St. Louis, MO). Tissue culture flasks and 24-well tissue 
culture plates were from Corning (Corning, NY).  
 
Cell Culture 
Human neuroblastoma SH-SY5Y cells (ATCC, Manassas, VA) were cultured in 
DMEM supplemented with 10% FBS, 100U/ml penicillin, and 100ug/ml streptomycin in 
75cm
2
 tissue culture flasks at 37
o
C in a humidified atmosphere of 5% CO2.  The cells 
were fed every 2-3 days and subcultured once they reached 80-90% confluence. For 
experiments, cells were differentiated in medium with 10µM Retinoic Acid (RA) for 5 to 
7 days.  
 
Cell Extract Preparation 
After experimental treatment, cells were pelleted by centrifugation at 300 x g at 
4
o
C for 10 min. Cells were then washed once with phosphate buffered saline (PBS) and 
resuspended in ice-cold 50mM potassium phosphate buffer, pH 7.0, containing 1mM 
EDTA and 0.1% Triton X-100.  The cell suspensions were sonicated, followed by 
centrifugation at 13,000g for 10 min at 4
o
C to remove cell debris. The resulting 
supernatants were collected and the protein concentrations were quantified with Bio-Rad 
protein assay dye kit (Hercules, CA) based on the method using bovine serum albumin 
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(BSA) as the standard [40]. The supernatants were then used for measurement of the 
antioxidants and phase 2 enzymes. 
 
Preparation of Mitochondrial Fraction 
Mitochondria were isolated from freshly harvested SH-SY5Y cells. Briefly, cells 
were washed once with PBS and centrifuged. The cell pellet was resuspended in 5ml 
sucrose buffer (0.25 M sucrose, 10mM Hepes, 1mM EGTA and 0.5% BSA, pH 7.4), 
homogenized in a Dounce tissue grinder on ice. The homogenate was centrifuged at 1500 
g for 10min at 4
o
C. The supernatant was collected and centrifuged at 10,000g for 10min 
at 4
o
C. The resulting mitochondrial pellet was washed twice with sucrose buffer and then 
resuspeneded in ice-cold 50mM potassium phosphate buffer, pH 7.0, containing 1mM 
EDTA and 0.1% Triton X-100, followed by sonication to lyse the mitochondria. The 
protein concentrations of mitochondrial lysates were measured as above. 
 
Assay for Glutathione (GSH) Content 
Total cellular and mitochondrial GSH content was measured according to the o-
phthalaldehyde-based flourometric method, which is specific for determination of GSH at 
pH 8.0[41, 42].  A volume of the extract was incubated at 4
o
C with 12.5µl of 25% 
metaphosphoric acid and a volume of 0.1 M sodium phosphate buffer containing 5mM 
EDTA for a final volume of 59.5µl for 10 min. The samples were centrifuged at 13,000g 
for 5min at 4
o
C. The resulting supernatant was incubated with .1ml of o-phthalaldehyde 
solution buffer for 15 min at room temperature. Flourescence intensity was then 
measured at an excitation wavelength of 350nm and an emission wavelength of 420nm. 
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The sample GSH content was calculated using a GSH (Sigma-Aldrich) standard curve, 
and expressed as nanomoles of GSH per milligram of sample protein. 
 
Assay for NAD(P)H: Quinone Oxidoreductase (NQO1) Activity 
Cellular and mitochondrial NQO1 activity will be measured according to methods 
previously described [43].  The reaction mix contained 50mM Tris-HCl (pH 7.5), 0.08% 
Triton X-100, 0.25 mM NADPH, and 80 uM 2,6-dichloroindophenol (DCIP). A volume 
of sample was added last for a final volume of 0.7 ml.  The reaction was conducted in the 
presence or absence of 60 µM dicumerol a potent inhibitor of NQO1. The two electron 
reduction of DCIP was monitored over 3 minutes at 25
o
C at a wavelength of 600nm. The 
dicumerol-inhibited NQO1 activity was calculated using the extinction coefficient of 21.0 
mM
-1
 cm
-1
, and expressed as nanomoles of DCIP reduced per minute per milligram of 
sample protein [25, 26].  
 
Assay for Glutathione Reductase (GR) Activity 
Cellular GR activity was measured according to the procedures described [43]. 
This assay is based on NADPH consumption coupled with reduction of the oxidized form 
of glutathione (GSSG) to GSH by GR. To a cuvette a volume of sample, 60µl of 20mM 
GSSG and 50mM potassium phosphate buffer (pH 7.0) and 1mM EDTA were added for 
a final volume of 0.54 mL. The cuvettes were incubated for 3 minutes at 37
o
C. The 
reaction was initiated by adding 60ul of 1.5mM NADPH. The subsequent consumption of 
NADPH was monitored at 340nm, 37
o
C for 5 min. The sample GR activity was 
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calculated using the extinction coefficient of 6.22nM
-1 
cm
-1
, and expressed as nanomoles 
of NADPH consumed per minute per milligram of sample protein. 
 
Assay for Glutathione Peroxidase (GPx) Activity 
Cellular GPx activity was measured based on the formation of GSSG from GPx-
catalyzed oxidation of GSH by H202, coupled with NADPH consumption in the presence 
of exogenously added GR. To a cuvette a volume of sample,50mM potassium phosphate 
(pH 7.0), 1mM EDTA and 2mM sodium azide, 60ul of 10mM GSH, 60 µl of glutathione 
reductase (2.4 U/ml), and 60 µl of 1.5mM NADPH for a final volume of 0.54 ml. The 
cuvette was incubated at 37
o
C for 3 min. After addition of 60 µl of 2 mM H202, the rate 
of NADPH consumption was monitored at 340 nm, 37
o
C for 5 min. The sample GPx 
activity was calculated using the extinction coefficient of 6.22 mM
-1 
cm
-1
, and expressed 
as nanomoles of NADPH consumed per minute per milligram of sample protein. 
 
Assay for Catalase Activity 
Cellular catalase activity was measured according to a method previously 
described. To a quartz cuvette volumes of sample and 50mM potassium phosphate buffer 
(pH 7.0) were added for a final volume of 0.42 ml. The reaction was initiated by adding 
0.18 ml of 30mM H202. The decomposition of H202 was monitored at 240nm, 25
o
C for 2 
min. The sample catalase activity was expressed as micromoles of H202 consumed per 
minute per milligram of sample protein.  
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MTT Reduction Assay 
Cell viability was determined by a modified MTT reduction assay, as described 
previously [42]. Cells were plated into 48-well tissue culture plates (1x10
6
 cells per well). 
After incubation of the cells in the presence of oxidative and electrophilic species for 24h 
at 37
o
C, the media was discarded followed by the addition of 0.4 ml of fresh DMEM 
supplemented with 0.5% FBS containing 0.2mg/ml MTT. The plates were incubated at 
37
o
C for another 2 h. The media was completely removed and to each well a mixture of 
dimethyl sulfoxide, isopropanol, and deionized water (1:4:5) was added so solubilize the 
formazan crystals. The amount of dissolved formazan was quantified at an absorbance of 
570nm.  
 
Statistical Analysis 
Statistical analysis was performed using SAS software (Cary, NC). All data are 
expressed as means ± SEM from at least three independent experiments unless otherwise 
indicated. Differences between mean values of multiple groups were analyzed by one-
way analysis of variance (ANOVA) followed by Tukey-Kramer test. Differences 
between two groups were analyzed by Student t-test. Statistical significance was 
considered at p < 0.05.  
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Results 
 
Effect of CDDO-Im on Cellular Antioxidants and Phase II Enzymes 
Shown in Figure 3A and 3B, SH-SY5Y cells express measurable basal levels of 
both GSH and NQO1.  Incubation of the cells with CDDO-Im at 1, 10, 25, 100, and 
400nM for 24 h led to induction of cellular GSH and NQO1. CDDO-Im at 10, 25, 100, 
and 400nM caused statistically convincing concentration dependent induction of GSH 
protein. Treatment of the cells with CDDO-Im at a concentration of 10nM resulted in a 
41% increase in cellular GSH. CDDO-Im treatment at 1nM caused a statistically 
significant increase of 48% in cellular NQO1 levels. In contrast to the results observed 
for GSH and NQO1, incubation of SH-SY5Y cells with CDDO-Im did not result in any 
statistically significant changes in the activities of cellular GPx, GR, or Catalase, as noted 
in Table 1. Similarly, no cellular GSH or NQO1 induction was observed in cells treated 
with therapeutic concentrations of Vitamin E (Fig 3c and 3d). 
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Figure 3. Cellular induction of GSH and NQO1 by CDDO-Im and Vitamin E. 
Concentration-dependent induction of GSH, NQO1 by CDDO-Im in RA-differentiated 
SH-SY5Y cells. Cells were incubated with the indicated concentrations of CDDO-Im for 
24 h, followed by measurement of cellular GSH content (A) and activities of NQO1 (B).  
For contrast, cells were incubated with 500nM and 200µM Vitamin E for 24 h and 
evaluated for GSH and NQO1 levels (C and D). Values represent means ± SEM from at 
least three separate experiments. *Indicates statistically convincing evidence (p < 0.05) of 
a difference compared to the control treatment. 
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Treatment 
GR 
(nmol/min/mg protein) 
GPx 
(nmol/min/mg protein) 
Catalase 
(nmol/min/mg protein) 
Control 25.70 ± 1.79 26.14 ± 1.42 4.87 ± 0.17 
1uM CDDO-Im 26.24 ± 3.87 27.27 ± 1.08 5.32 ± 0.29 
10uM CDDO-Im 27.75 ± 3.74 28.92 ± 1.09 4.42 ± 0.31 
25uM CDDO-Im 28.54 ± 2.67 25.55 ± 2.43 4.87 ± 0.20 
100uM CDDO-Im 27.75 ± 3.66 26.48 ± 1.95 5.36 ± 0.32 
400uM CDDO-Im 27.85 ± 3.73 24.58 ± 3.41 5.13 ± 0.21 
 
Table 1. Effects of CDDO-Im treatment on levels of GR, GPx and Catalase. Values 
represent means ± SEM from at least three separate experiments. No statistically 
convincing evidence of a difference was observed. 
 
Induction of Mitochondrial GSH and NQO1 by CDDO-Im 
GSH and NQO1 are known to be present in the mitochondria of mammalian cells. 
Additionally, the mitochondria are predominant targets of ROS damage. For these 
reasons we examined the levels/activities of both GSH and NQO1 in the isolated 
mitochondria of SH-SY5Y cells after treatment with CDDO-Im for 24 h. As shown in 
Figure 4, incubation of the cells with concentrations as low as 10nM of CDDO-Im led to 
a statistically significant induction of mitochondrial GSH and NQO1. 
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Figure 4. Mitochondrial induction of GSH and NQO1. Concentration dependent 
induction of mitochondrial GSH and NQO1   in RA-differentiated SH-SY5Y cells by 
CDDO-Im. The cells were incubated with 100 nM CDDO-Im for 24h, and then the 
mitochondria were isolated. Mitochondrial GSH level (A) and activities of NOQ1 (B) 
were measured as described in the “Materials and methods” section. Values represent 
means ± SEM from at least three separate experiments. *Indicates statistically convincing 
evidence (p < 0.05) of a difference compared to the control treatment. 
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Oxidase/Xanthine and H202 
XO/Xanthine and H202 are toxic exposures which are known ROS-generating 
compounds. XO/Xanthine is a known donor of superoxide radicals while H202 is a 
preliminary substrate in the creation of various ROS including superoxide and hydroxyl 
radicals. Antioxidants and phase 2 enzymes have been shown to play a critical role in the 
mitigation of ROS-induced damage. To determine if the elevated levels of GSH and 
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concentrations of XO in the presence of 0.5mM xanthine for 24h resulted in significant 
decreases in cell viability in a concentration-dependent manner. Similarly, Figure 5B 
depicts that incubation of control SH-SY5Y cells with various concentrations of H202 for 
24 h resulted in a significant decrease in cell viability in a concentration-dependent 
manner. Through our study, it was determined that at a concentration of 50µM 
XO/Xanthine there was a 70% reduction in cell viability. When cells were pretreated with 
100nM CDDO-Im, 50µM XO/Xanthine resulted in only a 25% reduction in cell viability.  
Similarly, in cells treated with 150µM H202, we observed a 70% reduction in cell 
viability, while cells pretreated with 100nM CDDO-Im for 24 h only experienced a 50% 
reduction in cell viability. The results indicate that pretreatment of the cells with CDDO-
Im at 100nM for 24 h afforded concentration dependent protection against the above 
ROS-mediated cell injury from both toxins. 
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Figure 5. CDDO-Im mediated protection against XO/Xanthine and H202 
cytotoxicity. Protective effects of CDDO-Im-pretreatment on ROS -mediated 
cytotoxicity in RA-differentiated SH-SY5Y cells. The cells were pretreated with or 
without 100nM CDDO-Im for 24 h, followed by incubation with various concentrations 
of XO (in the presence of 0.5 mM xanthine) or H2O2 for another 24 h. After this 
incubation, cell viability was determined using MTT reduction assay.  Values represent 
means ± SEM from 4 separate experiments. *Indicates statistically convincing evidence 
(p < 0.05) of a difference between Control treatment and 100nM CDDO-Im treatment at 
each toxin concentration. 
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Protective effect of CDDO-Im pretreatment on cytotoxicity by 3-Morpholinosydnonimine 
(SIN-1) 
The compound, SIN-1 is a known generator of peroxynitrite and nitric oxide 
during biological metabolism [44]. As noted in Figure 6, exposure of RA-differentiated 
SH-SY5Y cells to SIN-1 for 24 h resulted in a significant decrease in cell viability in a 
concentration-dependent manner. It was observed that the concentration-dependent 
cytotoxicity was attenuated by pretreatment of the cells with CDDO-Im at 100nM for 24 
h. In our study we observed that treatment of RA-differentiated SH-SY5Y cells with SIN-
1 at a concentration of 400µM caused a 21% reduction in cell viability and a 
concentration of 800µM showed a 73% reduction in cell viability. In contrast, when cells 
were pretreated with 100nM CDDO-Im, the cells showed only a 4% reduction and 26% 
reduction in cell viability respectively.   
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Figure 6. CDDO-Im mediated protection against SIN-1 cytotoxicity. Protective 
effects of CDDO-Im-pretreatment on SIN-1-mediated cytotoxicity in RA-differentiated 
SH-SY5Y cells. The cells were pretreated with or without 100nM CDDO-Im for 24 h, 
followed by incubation with various concentrations of SIN-1, a known peroxynitrite 
donor for another 24 h. After this incubation, cell viability was determined using MTT 
reduction assay.  Values represent means ± SEM from 4 separate experiments. *Indicates 
statistically convincing evidence (p < 0.05) of a difference between Control treatment and 
100nM CDDO-Im treatment at each toxin concentration. 
 
Protective effect of CDDO-Im pretreatment on cytotoxicity by 4-Hydroxy-2noneal (HNE) 
HNE is a lipid peroxidizer and a neurotoxic marker found in some individuals 
with neurodegenerative disorders [19]. Figure 7 shows that exposure of RA-differentiated 
SH-SY5Ycells to HNE for 24 h also significantly decreased cell viability in a 
concentration-dependent manner. When pretreated with 100nM CDDO-Im for 24 h, we 
have shown increased cell viability in SH-SY5Y cells. In our study, cells were exposed to 
10, 20, 40, 60, and 80 µM HNE and cell viability was measured using MTT assay. Our 
results in Figure 7 show that cells exposed to 60 µM HNE experienced an 87% reduction 
in cell viability while cells pretreated with 100nM CDDO-Im only showed a 46% 
reduction in cell viability. 
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Figure 7. CDDO-Im mediated protection against HNE cytotoxicity. Protective effects 
of CDDO-Im-pretreatment on HNE-mediated cytotoxicity in RA-differentiated SH-
SY5Y cells. The cells were pretreated with or without 100nM CDDO-Im for 24 h, 
followed by incubation with various concentrations of HNE, a known lipid peroxidizer 
for another 24 h. After this incubation, cell viability was determined using MTT 
reduction assay.  Values represent means ± SEM from 4 separate experiments. *Indicates 
statistically convincing evidence (p < 0.05) of a difference between Control treatment and 
100nM CDDO-Im treatment at each toxin concentration. 
 
Discussion 
It has become increasingly known that oxidative stress including environmental 
toxicant-mediated ROS damage in nervous tissue has contributed to neurodegenerative 
disorders such as PD [45, 46]. Studies have established that the brain and neuronal cell 
types remain some of the most vulnerable cell types to oxidative stress due to the fact  
that a high percentage of the oxygen consumed by the human body is allocated to brain 
function, and dopaminergic neurons have been shown to perform cellular respiration at a 
higher rate than other cell types [12, 47]. The high levels of respiration in these cells 
results in the creation of various types of ROS capable of damaging cellular lipids, 
proteins, DNA, and carbohydrates [48, 49]. ROS, such as super oxide radical, hydrogen 
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peroxide, and peroxynitrites have been found to be elevated in damaged and stressed 
neuronal tissue. Concurrently, depletion of antioxidant defense mechanisms, such as 
GSH, has become an early marker for PD [49]. Thus, it has become increasingly 
important to study therapies to induce antioxidant defense mechanisms such as GSH.  
In this study we utilize human SH-SY5Y cells differentiated with retinoic acid 
(RA) as an in vitro system to determine if the synthetic triterpenoid CDDO-Im can 
mediate the induction of key endogenous antioxidant defenses and provide a 
cytoprotective effect against various electrophilc and oxidative species [38, 39]. The 
design of this study shows that nanomolar concentrations of CDDO-Im can upregulate 
the antioxidant defenses GSH and NQO1 at both the cellular and mitochondrial levels. 
However, at the same time, CDDO-Im pretreatment did not result in any significant 
induction of GPx, GR, or Catalase. These results indicate that GSH and NQO1 may be 
regulated by distinct signaling pathways. In this regard the nuclear factor E2-related 
factor 2 (Nrf2) and its binding to the antioxidant response element have been found to be 
critical transcription steps for many cytoprotective genes in various cell types including 
CDDO-MA-treated SH-SY5Y cells [36]. Further study should be performed to determine 
if the Nrf2 signaling pathway is also responsible for the coordinated induction of 
antioxidant and phase 2 defenses by CDDO-Im in SH-SY5Y cells. 
GSH and NQO1 are two critical cellular defenses that protect neuronal cells 
against oxidative and electrophilic insults.  GSH is a tripeptide molecule which at 
increased concentrations has been shown to assist in the detoxification of many types of 
ROS including those associated with the pathophysiology involved in neurodegenerative 
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disorders such as PD [20, 50]. One of the earliest biochemical markers observed in 
patients with PD is a depletion of GSH content [51]. GSH behaves as a compound 
capable of direct removal of ROS as well as a substrate for a number of associated 
enzymes including GR, GPx, and GST. Ultimately, the network of GSH protective efforts 
has been shown to contribute to DNA repair, protein function, and synthesis of 
supportive enzymes and amino acids [52]. Many recent studies have shown that the 
regulation of GSH is a key component in normal cell function and the mitigation of 
oxidative stress. 
In addition to GSH, NQO1 is another endogenous compound associated with 
detoxification of ROS in neurodegenerative disorders [53]. NQO1 is an important cellular 
phase II enzyme, the main function of which is the metabolism of quinones to a more 
water-soluble derivative for removal from the body [54, 55]. More recently, NQO1 has 
also been implicated in direct ROS scavenging [56]. Specifically, NQO1 has been shown 
to directly autoxidize and detoxify superoxide radicals and hydrogen peroxide in various 
cell types [57].  Thus, our findings suggest that the coordinated induction of the 
endogenous antioxidant GSH and enzyme NQO1 by CDDO-Im may be a promising 
strategy for protecting against oxidative and electrophilic neuronal cell degeneration 
(Figure 3A and 3B).  
It is important to note that in addition to cellular antioxidant and phase 2 enzymes, 
marked induction of mitochondrial GSH content and NQO1 by CDDO-Im were also 
observed. Mitochondria are the predominant site of cellular respiration in the cell and are 
also extremely vulnerable to oxidative stress [58].  The high levels of respiration produce 
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excess ROS as a byproduct including superoxide, hydrogen peroxide, and hydroxyl 
radical [59, 60].  Mitochondrial dysfunction has also been found as a common symptom 
in PD pathogenesis [61-63]. Mitochondria do have their own endogenous ROS 
scavenging compounds, but during the etiology of the disease, the amount of ROS 
generation inevitably overwhelms the natural defenses of the cell [64].  Depleted amounts 
of mitochondrial GSH have been shown to directly result in increased levels of H202 and 
oxidative damage [65]. Thus, increasing the ROS defenses available to the cell and 
mitochondria is an important step in preventing dysfunction. Our study provides the 
important observation of the potential for mitochondrial antioxidant and phase II defenses 
since mitochondria dysfunction is a precursor to decreased cell viability and degenerative 
disorders such as PD (Figures 4A and 4B) [61-63].  
In addition to induction of antioxidant and phase II enzymes in RA-differentiated 
SH-SY5Y cells treated with CDDO-Im, this study, for the first time, observes the 
cytoprotective effect pretreatment with CDDO-Im can have on RA-differentiated SH-
SY5Y cells (Figure 2A). SH-SY5Y cells are generally classified as dopaminergic 
neurons, which possess many qualities of substantia nigra neurons with high levels of 
dopamine hydroxylase and tyrosine hydroxylase [39, 66]. The pretreatment of these cells 
with retinoic acid further matures them to resemble neuronal cell types by slowing their 
proliferation and changing their morphology to more closely resemble dopaminergic 
neurons. We observed that the coordinated induction of cellular defenses was 
accompanied by augmented resistance of these cells to oxidative damage induced by 
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super oxide donors such as XO/xanthine and H202, nitric oxide/peroxynitrate derived 
from SIN-1, and lipid peroxidation caused by HNE.  
XO/xanthine and H202 are widely used superoxide radical donors and have 
previously been shown to induce oxidative stress in various cell types [67, 68]. In our 
study we used these two exogenous toxins as a way to increase the oxidative stress on 
RA-differentiated SH-SY5Y cells. H202 is a prolific and yet stable form of ROS making it 
able to pass through cellular barriers before being metabolized to the more reactive 
superoxide and hydroxyl radicals [69]. H202 is of particular interest since it is a byproduct 
of dopamine turnover in dopaminergic neurons and may be associated with the 
accelerated cell degeneration associated with PD [70]. XO/xanthine acts as a single 
electron donor to normal 02 molecules forming the superoxide radical [71]. The 
superoxide radical has been implicated in disrupting enzyme function and damaging 
nucleic acids [72, 73]. In our study we utilize H202 and XO/xanthine as systems to 
increase oxidative stress in SH-SY5Y cells. Our results show statistically convincing 
evidence that treatment with CDDO-Im reduces the cytotoxicity of ROS generated by 
XO/xanthine and H202 (Figures 5A and 5B). 
Cellular dysfunction causing ROS also includes nitrogenous compounds including 
nitric oxide (NO) which readily reacts with the superoxide radical to form the highly 
reactive peroxynitrite compound [74]. SIN-1 is a known peroxynitrite donor in cellular 
metabolism and has been found to cause direct oxidative damage to various cell types 
[44].  Peroxynitrite molecules cause oxidative damage to key cellular proteins and 
nucleic acids, altering cell signaling function and decreasing cell viability [75]. 
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Peroxynitrite and NO have also been found to induce apoptosis in SH-SY5Y cells [76-
78].  In our study, these results show that CDDO-Im pretreatment is correlated to a 
mitigation of SIN-1-mediated cytotoxcity (Figure 6). 
In addition to SIN-1, we tested the impact exposure HNE would have on RA-
differentiated SH-SY5Y cells and the effect pretreatment with CDDO-Im would have on 
cell viability. HNE is a reactive aldehyde compound capable of lipid peroxidation 
damage which disrupts the integrity of the lipid membrane of the cells and ultimately 
reduces cellular viability [79, 80]. Specifically, HNE has been implicated in a range of 
cytopathological effects including inhibition of protein function, DNA transcription, and 
cellular signaling [79]. Routinely, autopsied brain tissue from PD patients has been 
shown to contain increased levels of protein carbonyl damage and HNE, both indicative 
of oxidative damage to the central nervous system (CNS) [81, 82]. Our treatment 
concentrations were chosen to be biologically relevant since HNE adducts have been 
found at concentrations up to 40 µM in the CNS. Our results indicate that pretreatment 
with CDDO-Im is capable of protecting against HNE-mediated toxicity in a 
concentration dependent manner (Figure 7). 
In conclusion, pretreatment of RA-differentiated SH-SY5Y cells with CDDO-Im 
significantly elevates both cellular and mitochondrial concentrations of GSH and NQO1. 
More importantly, the pretreatment has been shown to effectively mitigate a reduction in 
cell viability caused by ROS-generating compounds: XO/xanthine, H202, SIN-1, and 
HNE. Overall, our results demonstrate that CDDO-Im may be a potent and novel 
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treatment option for mitigating neurodegeneration and ultimately slowing the progression 
of disorders such as Parkinson’s disease (Figure 8). 
 
 
Figure 8. Diagram of proposed cytoprotection by CDDO-Im. 
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CHAPTER III 
THE MECHANISTIC ROLE OF GSH IN CDDO-IM MEDIATED PROTECTION 
AGAINST ACROLEIN-INDUCED NEUROCYTOTOXICITY 
 
Introduction 
Acrolein is a ubiquitous environmental toxin formed during the combustion of 
organic matter. The toxin is found in many pesticide products and in all forms of smoke, 
including automobile exhaust and cigarettes[5]. An exogenous reactive aldehyde, 
acrolein, has been found to readily peroxidize lipids including the fatty acid rich nerve 
cell types [6]. Recent studies show that the resulting oxidative damage leads to decreased 
cell proliferation and increased apoptosis [7, 8]. Acrolein can also be formed inside the 
cell as a product of lipid peroxidation by other forms of ROS [4]. Neuronal cell exposure 
to acrolein and other (ROS) generating compounds and the subsequent cellular damage 
are found to be associated with the progression of Parkinson’s Disease as well as other 
neurodegenerative disorders [9, 10]. Elevated concentrations of acrolein, up to 40µM, 
have been found in the brain tissue of PD patients and are considered a specific marker 
for lipid peroxidation damage [7, 11]. Formation of these acrolein-protein adducts have 
been implicated in the pathogenesis of neurodegenerative disorders including PD [9, 10].  
Acrolein causes damage to biomolecules including lipids, protein, and DNA damage 
leading to cell death and neurodegeneration [4]. In addition to direct oxidative damage, 
acrolein also plays a role in the depletion of beneficial antioxidant defenses such as
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cellular glutathione (GSH) [8, 83]. Thus, treatment options designed to upregulate the 
natural cellular antioxidant defenses were found to partially protect against substantia 
nigra degeneration in animal models [84, 85]. 
 Studies have shown that GSH, glutathione-s-transferase (GST), and aldose 
reductase (AR) play important roles in the detoxification of acrolein [21, 86]. Foremost 
among these is GSH, a tripeptide thiol consisting of glutamate, cysteine, and glycine with 
higher levels in neuronal cells [87]. GSH is capable of conjugating reactive species and is 
also aided by other enzymatic antioxidants to detoxify peroxides in the cell [88]. It has 
been suggested that GST utilizes GSH as a cofactor in its detoxification process of 
eledtrophilic aldehydes [89]. Similarly, AR has been shown to utilize a binding site on 
GSH to detoxify the GSH-adlehyde conjugates [90, 91]. Due to the limited successes 
using exogenous antioxidants, many studies have been focused on the increase of the 
endogenous antioxidant capabilities of the cells, including GSH, against oxidative injury. 
Thus, regulation of GSH, GST, and AR could be an important defense mechanism 
against acrolein-induced neurological disorders. In our study we proposed a novel 
strategy for protective intervention of PD through the upregulation of endogenous 
antioxidant defenses in neuronal SH-SY5Y cells mediated by the synthetic triterpenoid 
compound 2-Cyano-3,12-dixooleana-1,9-dien-28-imidazolide (CDDO-Im). Triterpenoids 
are steroid like compounds derived from plant extracts which have shown to have 
numerous protective/therapeutic effects on various cell types[28].  Various forms of 
CDDO have also been utilized in clinical trials as an anti-cancer proliferation treatment 
and an anti-inflammatory agent for rheumatoid arthritis [31-34]. 
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We have recently found that CDDO-Im at low concentrations, within an 
achievable plasma range, significantly induces GSH and NQO1 in RA-differentiated SH-
SY5Y cells conferring protection against reactive oxidative and electrophilic species. 
However, the effects of CDDO-Im in ameliorating the toxic effects of acrolein remain 
unknown. Furthermore, it remain unclear the roles of GSH, GST, and AR in CDDO-Im 
mediated cytoprotection against acrolein toxicity.  In this study, we determined the 
protective effect of CDDO-Im against acrolein-induced cytotoxicity and its potential for 
induction of GSH, GST, and AR to elicit its protective effect in RA-differentiated SH-
SY5Y cells.  Additionally, we further identified the mechanism by which CDDO-Im 
mediates protection through the prevalence of GSH. 
 
Materials and Methods 
 
Chemicals and Materials 
Dulbecco’s modified Eagle’s medium (DMEM), penicillin streptomycin, and fetal 
bovine serum (FBS) were obtained from Gibco-Invitrogen (Carlsbad, CA). CDDO-Im [2-
Cyano-3,12-dixooleana-1,9-dien-28-imidazolide] was obtained from Toronto Research 
Chemicals Inc. ( Toronto, Canada). Acrolein, GSH, Retinoic Acid (RA), 1-chloro-
2,4dinitrobenzene (CDNB), o-phtalaldehyde, 3-[4,5-dimethylthiazol-2yl]-2,5-
diphenyltertrazolium bromide (MTT) were from Sigma Chemical (St. Louis, MO). 
Tissue culture flasks and 24-well tissue culture plates were from Corning (Corning, NY). 
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Cell Culture 
Human neuroblastoma SH-SY5Y cells (ATCC, Manassas, VA) were cultured in 
DMEM supplemented with 10% FBS, 100U/ml penicillin, and 100ug/ml streptomycin in 
75cm
2
 tissue culture flasks at 37
o
C in a humidified atmosphere of 5% CO2.  The cells 
were fed every 2-3 days and subcultured once they reached 80-90% confluence. For 
experiments, cells were differentiated in medium with 10µM Retinoic Acid (RA) for 5 to 
7 days.  
 
Cell Extract Preparation 
After experimental treatment, cells were pelleted by centrifugation at 300 x g at 
4
o
C for 10 min. Cells were then washed once with phosphate buffered saline (PBS) and 
resuspended in ice-cold 50mM potassium phosphate buffer, pH 7.0, containing 1mM 
EDTA and 0.1% Triton X-100.  The cell suspensions were sonicated, followed by 
centrifugation at 13,000g for 10 min at 4
o
C to remove cell debris. The resulting 
supernatants were collected and the protein concentrations were quantified with Bio-Rad 
protein assay dye kit (Hercules, CA) based on the method of Bradford (Bradford, 1976) 
using bovine serum albumin (BSA) as the standard. The supernatants were then used for 
measurement of the antioxidants and phase 2 enzymes. 
 
Assay for Glutathione (GSH) Content 
Total cellular and mitochondrial GSH content was measured according to the o-
phthalaldehyde-based flourometric method, which is specific for determination of GSH at 
pH 8.0[41, 42].  A volume of the extract was incubated at 4
o
C with 12.5µl of 25% 
34 
 
metaphosphoric acid and a volume of 0.1 M sodium phosphate buffer containing 5mM 
EDTA for a final volume of 59.5µl for 10 min. The samples were centrifuged at 13,000g 
for 5min at 4
o
C. The resulting supernatant was incubated with 0.1ml of o-phthalaldehyde 
solution buffer for 15 min at room temperature. Fluorescence intensity was then 
measured at an excitation wavelength of 350nm and an emission wavelength of 420nm. 
The sample GSH content was calculated using a GSH (Sigma-Aldrich) standard curve, 
and expressed as nanomoles of GSH per milligram of sample protein. 
 
Assay for Glutathione S-transferase (GST) Activity 
Cellular GST activity was measured according to the method described previously 
using 1-chloro-2,4-dinitrobenzene (CDNB) as a substrate[92]. The reaction mix was 
made containing 1 mM GSH, 1mM CDNB, and 3 mg/ml bovine serum albumin in 0.1 M 
sodium phosphate buffer (pH 6.5).  The above reaction mix was added to a cuvette with a 
volume of sample for a final volume of 0.6 ml. The subsequent rate of formation of 
CDNB-GSH conjugate was monitored at 340 nm, 25
o
C for 5 min. The sample GST 
activity was calculated using the extinction coefficient of 9.6 nM
-1 
cm
-1
, and expressed as 
nanomoles of CDNB-GSH conjugate formed per minute per milligram of sample protein. 
 
Assay for Aldehyde Reductase (AR) Activity 
Cellular AR activity was measured using a modified method as described 
previously [93, 94]. To a cuvette 50mM potassium phosphate buffer, pH 6.0, 0.4 M 
Li2SO4, 10mM D,L-glyceraldehyde and 100uM NADPH was added. The reaction was 
initiated by adding 50µl sample. Activity was measured by monitoring of the subsequent 
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consumption of NADPH spectrophotometrically at 340nm, 25
o
C for 5 min. The sample 
AR activity was expressed as nanomoles of NADPH consumed per minute per milligram 
of cellular protein. 
 
MTT Reduction Assay 
Cell viability was determined by a modified MTT reduction assay, as described 
previously [42]. Cells were plated into 48-well tissue culture plates (1x10
6
 cells per well). 
After incubation of the cells in the presence of oxidative and electrophilic species for 24h 
at 37
o
C, the media was discarded followed by the addition of 0.4 ml of fresh DMEM 
supplemented with 0.5% FBS containing 0.2mg/ml MTT. The plates were incubated at 
37
o
C for another 2 h. The media was completely removed and to each well a mixture of 
dimethyl sulfoxide, isopropanol, and deionized water (1:4:5) was added so solubilize the 
formazan crystals. The amount of dissolved formazan was quantified at an absorbance of 
570nm.  
 
Carbonyl Reduction Assay 
Cell extract was prepared as described above and carbonylation of cell extract was 
performed according to methods described previously [95]. Firstly, 300 µL of DNPH 
reagent was combined with 75 µL sample in a micro centrifuge tube and incubated at 
room temperature in the dark and mixed by vortex every 15 minutes. At the same time a 
control tube of 75 µL sample and 300 µL 2M HCL was prepared in exactly the same 
manner. Next added 375 µL 20% TCA and mixed by vortex, incubated on ice for 5 
minutes. The cells were centrifuged for 10 min at 4
o
C, supernatant discarded, and the 
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supernatant resuspended in 375 µL 10% TCA on ice for 5 min. Repeat previous wash 
sequence and discard supernatant. The pellet was then resuspended in 500 µL of ethanol: 
ethyl acetate (1:1) mixture and resuspended pellet with a spatula. After repeating wash 
resuspend the pellet with 500 µL 6 M guanidine hydrochloride and vortex. Centrifuge 
again and remove any leftover debris. Transfer 220 µL of supernatant into a 96 well plate 
and measure at wavelength 370 nm wavelength. 
 
TBARS Assay 
Cell extract was prepared as above with the exception that the whole homogenate 
will be used for testing in a modified method measuring TBARS[96]. Firstly, 50 µL cell 
extract, 50 µL 8.1 % SDS, 375 µL 20% acetic acid, 375 µL 0.8% TBA and 150 µL 
deionized water. The tubes were then placed in an incubator at 95
o
C for 60 min.  After 
cooling, samples and standards were read at 532nm. Results were expressed in 
nanomoles MDA per milliliter of protein.  
 
Assay for Lactate Dehydrogenase (LDH) Release 
LDH is an intracellular enzyme which leaks out from cells due to plasma 
membrane damage and is widely used to determine cytotoxicity as described previously 
[97]. RA-differentiated SH-SY5Y cells were treated with DMEM medium with 1% FBS. 
After incubation the cell culture medium was collected from the cell culture and 
centrifuged. The supernatant was collected in a new tube for assay. To an assay cuvette, 
50µl of the collected culture medium 30µL 5.5mM sodium pyruvate, and 490µl PBS 
were added. To initiate the reaction 30µl 3mg/ml NADH was added. The LDH-catalyzed 
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NADH activity was expressed as nanomoles of NADH consumed per minute per 
milliliter of culture medium. 
 
Statistical Analysis 
Statistical analysis was performed using SAS software (Cary, NC). All data are 
expressed as means ± SEM from at least three independent experiments unless otherwise 
indicated. Differences between mean values of multiple groups were analyzed by one-
way analysis of variance (ANOVA) followed by Tukey-Kramer test. Differences 
between two groups were analyzed by Student t-test. Statistical significance was 
considered at p < 0.05. 
 
Results 
 
Protective effects of CDDO-Im pretreatment on acrolein-induced cytotoxicity 
Cellular antioxidants/enzymes play important roles in protecting cells against 
oxidative stress induced neuronal damage. We recently found that various cellular 
antioxidant/phase 2 enzymes can be induced by CDDO-Im in RA-differentiated SH-
SY5Y cells. Because of the critical involvement of acrolein and antioxidant defenses in 
the pathogenesis of neurodegenerative diseases, we investigated the cytoprotective effects 
of CDDO-Im pretreatment on acrolein-induced toxicity in RA-differentiated SH-SY5Y 
cells. RA-differentiated SH-SY5Y cells were tested in response to exposure to acrolein 
for 24 h with or without a 24 h pretreatment of 100nM CDDO-Im. Control cells showed a 
decrease in cell viability when treated with acrolein at concentrations of 20, 40, and 80 
µM for 24 h. Conversely, the cells pretreated with 100nM CDDO-Im for 24 h showed a 
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concentration dependent significant increase in cell viability when treated with acrolein 
under the same conditions, as determined by the MTT assay. Pretreatment of SH-SY5Y 
cells with CDDO-Im afforded a dramatic protection against acrolein-induced toxicity 
when compared to treatment with Vitamin E (Fig. 9). We also visualized the cellular 
damage to RA-differentiated SH-SY5Y cells and observed that pretreatment with 100nM 
CDDO-Im resulted in a less dramatic change in cell morphology when exposed to 40 µM 
acrolein(Fig 10). 
 
 
Figure 9. Effects of CDDO-Im pretreatment on acrolein-induced cytotoxicity. In 
panel A, RA-differentiated SH-SY5Y cells were treated with and without 100nM CDDO-
Im for 24 h followed by 10-80 µM acrolein. In panel B, cells were pretreated with 100nM 
CDDO-Im or 200 µM Vitamin E for 24 h followed by exposure to 40 µM acrolein for 24 
h. After incubations, cytotoxicity was determined by MTT reduction assay   Values 
represent means ± SEM from at least three separate experiments. *Indicates significantly 
convincing difference (p < 0.05) from the respective control group.    
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Figure 10. Phase-contrast microscopy. Panel A shows control RA-differentiated SH-
SY5Ycells, panel B shows cells treated with 100nM CDDO-Im for 24 h, panel C shows 
cells treated with 40 µM acrolein for 24 h and panel D shows cells pretreated with 
100nM CDDO-Im for 24 h followed by 40 µM acrolein for 24 h.  
  
Effects of CDDO-Im treatment on GSH content and GST and AR activity 
We recently showed that incubation of RA-differentiated SH-SY5Y cells with 10, 
25, 100, and 400 µM CDDO-Im for 24 h resulted in significant increases in total cellular 
GSH content in a concentration dependent fashion. Because, GST and AR play a critical 
role in detoxification of acrolein, we next determined whether the activities of GST and 
AR are altered by CDDO-Im.  As shown in Figure 11, panel A depicts that RA-
differentiated SH-SY5Y cells treated with 100nM CDDO-Im for 24 h resulted in a 
significant increase in cellular GSH but not in GST or AR. In panel B, the mediated 
BA
C D
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induction of GSH by 100nM of CDDO-Im is further determined to occur in a time 
dependent manner.  
 
 
Figure 11. Effect of CDDO-Im treatment on GSH, GST, and AR. Effects of CDDO-
Im treatment on cellular levels of GSH, GST, and AR (A) in RA-differentiated SH-SY5Y 
cells. Cells were incubated with 100 nM CDDO-Im followed by measurement of cellular 
GSH content and activities of GST and AR (panel A). Panel B depicts a time dependent 
increase in cellular GSH in RA-differentiated SH-SY5Y cells treated with 100nM 
CDDO-Im. Values represent means ± SEM from at least three separate experiments. 
*Indicates significantly convincing difference (p < 0.05) from the respective control 
group. 
 
GSH depletion by acrolein 
Next we investigated the role of GSH in detoxification of acrolein. To this end we 
determined if acrolein could cause depletion of cellular GSH content in RA-differentiated 
SH-SY5Y cells. Figure 12A indicates that cells incubated with 40 µM acrolein for 0.5-6 
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h resulted in a significant depletion of cellular GSH. While Figure 12B indicates the GSH 
depletion precedes the decrease in cell viability as noted by the LDH release into cell 
culture media. Significant depletion of cellular GSH is observable at the 0.5 h time point 
while significant LDH increase is observed at the 2 h time point. 
 
 
Figure 12. Time dependent acrolein-induced GSH depletion and LDH release. Panel 
A shows that RA-differentiated SH-SY5Y cells treated with 40µM acrolein exhibit a time 
dependent depletion of cellular GSH levels. Panel B depicts treatment with 40µM 
acrolein results in a time dependent increase in cellular LDH released. Values represent 
means ± SEM from at least three separate experiments. *Indicates significantly 
convincing difference (p < 0.05) from the respective control group. 
  
Effects of BSO pretreatment on acrolein-induced cytotoxicity 
BSO is a known specific inhibitor of the GSH subunit gamma-glutamylcysteine 
synthetase (GCLC) and has been widely used for depleting intracellular GSH in various 
cell types. As shown in Figure 13A, incubation of RA-differentiated SH-SY5Y cells with 
25, 50, and 100 µM BSO for 24 h caused a 50-80% decrease in total cellular GSH 
without any change in cell viability as seen in LDH release and MTT assay results 
(Figure 13B and 13C). In Figure 13D cells were pretreated with and without 25 µM BSO 
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for 24 h, and then exposed to various concentrations of acrolein for another 24 h. The 
observed MTT assay indicates that pretreatment with BSO for 24 h resulted in a 
significant potentiation of acrolein-induced cytotoxicity when compared to cells without 
BSO, particularly at the 20µM concentration. 
 
 
Figure 13. BSO depletion of cellular GSH and reduced cell viability. Effects of BSO 
treatment on cellular GSH and acrolein-induced cytotoxicity in RA-differentiated SH-
SY5Y cells. Panel A and B depict cell viability of SH-SY5Y cells in the presence of BSO 
at the indicated concentrations for 24 h as measured by MTT (A) and LDH (B). Panel C 
depicts the effect of BSO treatments at various concentrations on GSH level. In panel D 
the cells were incubated with or without 25µM BSO for 24h prior to the media being 
removed and the cells exposed to the indicated concentrations of acrolein for another 24h, 
followed by the determination of cell viability by MTT reduction assay. Values represent 
means ± SEM from at least three separate experiments. *Indicates significantly 
convincing difference (p < 0.05) from the respective control group. 
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Effects of BSO cotreatment on CDDO-Im mediated cytoprotection against acrolein-
induced cytotoxicity 
To further examine the causal role of GSH in CDDO-Im mediated protection 
against acrolein toxicity, we examined the resultant GSH and cell viability from co 
treatment with CDDO-Im, BSO, and then Acrolein. RA-differentiated SH-SY5Y cells 
were pretreated with 100nM CDDO-Im in the presence or absence of 25 µM BSO 
followed by exposure to 40 or 20 µM acrolein. 40µM acrolein alone or 20µM acrolein in 
the presence of 25 µM BSO were chosen as they were the lowest concentrations to 
induce at least a 65% decrease in cell viability (Figures. 9A and 13D). Shown in Figure 
14A, cotreatment of cells with CDDO-Im and BSO prevented the GSH induction 
observed with CDDO-Im alone resulting in a reduced cellular concentration level. Figure 
14B represents a comparative study in GSH induction in the presence of acrolein as 
observed in the MTT assay. Incubation of cells treated with 40µM acrolein alone for 24 h 
led to an 83% decrease in cell viability. Secondly, incubation of cells pretreated with 
CDDO-Im for 24 h, followed by 40 µM acrolein for 24 h resulted in significant cellular 
protection against acrolein-induced cytotoxicity. Incubation of cells pretreated with 25 
µM BSO followed by 20 µM acrolein resulted in a significant decrease in cell viability. 
Similarly, pretreatment of cells with 100nM CDDO-Im with 25 µM BSO followed by 20 
µM acrolein resulted in a significant 51% decrease in cell viability, reducing the 
protective effect of CDDO-Im. Depletion of cellular GSH by BSO dramatically prevents 
the CDDO-Im mediated cytoprotective effects on acrolein-induced toxicity.  
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Figure 14. Effects of BSO co-treatment on CDDO-Im mediated cytoprotection. 
Effects of cotreatment with BSO on CDDO-Im mediated induction of GSH (A) and 
protection against acrolein cytotoxicity (B) in SH-SY5Y cells.  In panel A, Cells were 
incubated with 100nM CDDO-Im, 25µM BSO, or 25µM BSO + 100nM CDDO-Im for 
24 h, followed by measurement of cellular GSH content. In panel B, cells were cultured 
in a 48 well plate incubated with 100nM CDDO-Im, 25µM BSO, or 25µM BSO + 
100nM CDDO-Im for 24 h. The media was removed and the cells were then cultured in 
the presence or absence of 40µM or 20µM acrolein for 24 h, followed by determination 
of cell viability by MTT reduction assay. Values represent means ± SEM from at least 
three separate experiments. *Indicates significantly convincing difference (p < 0.05) from 
the respective control group. #Indicates a significant difference from the 100nM CDDO-
Im group. &Indicates a significant difference from 40µM Acrolein +100nM CDDO-Im 
group. 
 
Effect of CDDO-Im co-treatment with BSO on acrolein-mediated lipid peroxidation and 
protein damage. 
 In order to further investigate the cellular damage associated with acrolein 
exposure, we studied the amount of protein and lipid damage in RA-differentiated SH-
SY5Y cells exposed to 40 µM acrolein for 24 h. In Figure 15, panel A depicts Protein 
Carbonyl concentration, a marker of protein damage incurred by cells exposed to acrolein 
and pretreated with and without CDDO-Im and BSO for 24 h. Panel B depicts the amount 
of Thiobarbituric Acid reactive substances (TBARS), a maker of lipid peroxidation, in 
cells treated with 40 µM acrolein for 24 h and pretreated with and without CDDO-Im and 
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BSO for 24 h. In both cases an elevated amount of protein carbonyl and TBARS is 
measured in cells treated with 40 µM acrolein compared to control cells and cells 
pretreated with 100nM CDDO-Im for 24 h. Pretreatment of SH-SY5Y cells with CDDO-
Im afforded a dramatic protection against acrolein-induced lipid peroxidation and protein 
damage.  When cells were pretreated with 25 µM BSO in addition to CDDO-Im, the 
protein carbonyl and TBARS again was observed to be significantly elevated. These 
results further confirmed that GSH played a predominant role in CDDO-Im-mediated 
cytoprotection against acrolein toxicity. 
 
 
Figure 15. Acrolein induced protein and lipid damage. BSO prevents the CDDO-Im 
mediated cytoprotection against acrolein-induced lipid peroxidation and protein damage 
in RA-differentiated SH-SY5Y cells. Protein Carbonyl (A) and TBARS (B) was 
measured in cells treated with 40 µM acrolein alone for 24 h, and with pretreatment with 
and without 100nM CDDO-Im and 25 µM BSO for 24 h. Values represent means ± SEM 
from at least three separate experiments. *Indicates significantly convincing difference (p 
< 0.05) from the untreated control group. #Indicates a significant difference from the 
100nM CDDO-Im treated group. 
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Discussion 
The reactive aldehyde acrolein is a major byproduct of oxidative stress and 
particularly lipid peroxidation, which has been implicated in the pathogenesis of 
neurodegeneration [9, 10]. Acrolein is a ubiquitous and potent reactive aldehyde and 
acrolein-protein adducts have been established as an important cellular marker in 
autopsies of PD patients [8, 83]. Several endogenous cellular factors, including GSH, 
AR, and GST, have been suggested to play important roles in the detoxification of 
acrolein [21, 86].  Our results indicate that RA-differentiated SH-SY5Y cells are capable 
of expressing basal levels/activities of GSH, AR, and GST, and CDDO-Im pretreatment 
protects cells against acrolein induced cytotoxicity. Incubation with low nanomolar 
concentrations of CDDO-Im resulted in significant induction of GSH. Conversely, the 
same concentrations of CDDO-Im failed to significantly induce activities of GST and 
AR, indicating that in SH-SY5Y cells, these two aldehyde-detoxifying enzymes may be 
regulated via distinct signaling pathways (Figure 9).  Our results further indicate that 
elevation of cellular GSH, while not GST or AR is a primary mechanism underlying 
CDDO-Im-mediated protection against acrolein toxicity in RA-differentiated SH-SY5Y 
cells.   
 The main tripeptide antioxidant GSH has been suggested by many studies to 
attenuate the oxidative damage underlying various neurodegenerative disorders, 
including PD[98]. At the same time a depletion of cellular GSH has been discovered as 
an early cellular marker for PD. In this study we demonstrate that acrolein-induced GSH 
depletion preceded the loss of cell viability (Figure 12A and B). This result suggests that 
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cellular GSH depletion may be an important early event in acrolein-induced cytotoxicity 
in RA-differentiated SH-SY5Y cells. Since it has been established that GSH is able to 
directly react with acrolein to form less reactive protein conjugates, the direct GSH- 
aldehyde interaction would account for the early depletion of GSH after initial exposure 
while the decrease in cell viability occurs after the GSH levels are depleted [99]. The 
initial depletion of GSH preceding the loss in viability also corroborates the report that 
GSH is an imperative cellular component in detoxification of reactive aldehydes 
including acrolein [100]. To further study the involvement of GSH depletion on acrolein 
cytotoxicity in SH-SY5Y cells, BSO was utilized to deplete cellular GSH. According to 
our results, BSO is a potent inhibitor of GSH and does not cause a decrease in cell 
viability or cause any damage to the cell membrane (Figures 13A, 13B, and 13C). 
Pretreating cells with BSO for 24 h prior to acrolein for 24 h resulted in a concentration 
dependent potentiation of acrolein-induced toxicity at a faster rate than cells not treated 
with BSO (Figure 13D). To provide evidence of GSH involvement CDDO-Im-mediated 
detoxification of acrolein, RA-differentiated SH-SY5Y cells were pretreated with 
CDDO-Im in the presence and absence of 25µM BSO followed by exposure to 20 or 40 
µM acrolein. In this experiment, cells co-treated with BSO and CDDO-Im showed a 
reduced induction of GSH, significantly less than CDDO-Im alone (Figure 14A). When 
then treated with acrolein, the BSO inhibition of GSH reduced the CDDO-Im mediated 
cytoprotective effects by more than 50% (Figure 14B). Our observations indicate that 
elevated levels of cellular GSH are a primary mechanism underlying CDDO-Im-mediated 
protection against acrolein toxicity in RA-differentiated SH-SY5Y cells. 
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 To further demonstrate the role of GSH involvement in in CDDO-Im-mediated 
cytoprotection against acrolein toxicity, we measured the protein and lipid damage 
incurred on RA-differentiated SH-SY5Y cells exposed to acrolein (Figure 15A and 15B) 
in presence of CDDO-Im. The main damage to cells occurs as a result of acrolein-
induced alterations to macromolecules such as membrane lipids and proteins which are 
responsible for maintaining normal cell function. In our observations, treatment with 
CDDO-Im significantly reduces the amount of protein carbonyl and TBARS measured in 
cells treated with 40 µM acrolein for 24 h. Also, we observed that co-treatment with 
CDDO-Im and BSO resulted in elevated levels of both markers similar to those observed 
in cells exposed to 40 µM acrolein alone. Similar to our cell viability results above, our 
observations indicate that elevated levels of cellular GSH are a primary mechanism 
underlying CDDO-Im-mediated reduction of acrolein induced protein and lipid damage 
in RA-differentiated SH-SY5Y cells. 
It is important to note that these studies cannot exclude the possibility that other 
mechanisms may be also involved in CDDO-Im-mediated protection as the BSO 
inhibition did not completely reverse its protective effects. Thus, more study is needed to 
fully understand the CDDO-Im protective mechanisms. Acrolein research has established 
that the primary observed cause for cell death occurs via apoptosis and impacts various 
transcription factors. In lung tissue, acrolein toxicity has been found to activate the p53 
apoptosis pathway leading to cell death [101]. Similarly, the activation of the growth 
related transcription factor NF-kB is also affected by ROS and acrolein[102, 103]. GSH 
is necessary for the activation of the NF-kB signaling pathway and acrolein depletion of 
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GSH may contribute to varying activation depending on dose and duration of 
exposure[104]. In a study using SK-N-SH human neuroblastoma cells, acrolein exposure 
resulted in a biphasic depletion/increase in GSH accompanied by a similar 
decrease/increase in NF-kB activation [105]. In a SH-SY5Y cell, Yang et. al. has shown 
that the CDDO-Methyl Amide has been shown to interact with the Keap-1, Nrf2, and 
ARE elements to influence gene transcription for endogenous antioxidant enzymes[36]. 
However, whether acrolein cytotoxicity occurs in a similar fashion and protection by 
CDDO-Im is regulated by similar pathways in neuronal cells remain unknown.  
 Increased oxidative stress by acrolein combined with the reduced endogenous 
GSH and other atioxidants is an important underlying risk factor for the development of 
neurodegenerative disorders such as PD. Accordingly, acrolein induced toxicity has been 
linked to many neurodegenerative disorders such as Parkinson’s disease [51, 106, 107]. 
The potential treatment option of GSH itself is limited since it does not readily pass 
through the blood brain barrier and may be limited by glial cell metabolism if it is able to 
enter the CNS[108]. Thus, a great deal of research has been conducted regarding 
potential therapeutic treatments focused on the use of exogenous antioxidant compounds 
[109-111]. However,  both in vitro and in vivo models have shown that treatment with 
exogenous vitamins and antioxidant compounds are limited in their bioavailability, 
permeability, and are metabolized at a rate exceeding that of the oxidative damage [112, 
113]. While studies with transgenic models have yielded the most convincing evidence 
for the role of a particular antioxidant enzyme in protecting against oxidative injury, 
using such an approach in humans is not yet feasible [114-119].  CDDO-Im is a lipophilic 
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compound and most likely would be able to penetrate the blood brain barrier as it has 
been shown in other CDDO compositions[36]. This study for the first time indicates that 
CDDO-Im can be used at nanomolar concentrations to induce cytoprotection against the 
reactive aldehyde acrolein toxicity, suggesting it is a promising agent in ameliorating 
lipid peroxidation damage and neurodegeneration. Our results indicate that cellular GSH 
can be potently elevated through the use of CDDO-Im at nanomolar concentrations. 
Additionally, the upregulation of the GSH system appears to be the predominant factor in 
protection against acrolein-induced toxicity.  In this regard, our results suggest that the 
increase in endogenous GSH by CDDO-Im could be a novel strategy against reactive 
aldehyde-induced neurotoxicity. 
The acrolein concentrations used in our study range from 10 to 80 µM. These 
concentrations have been found to be biologically relevant in various cell types. Studies 
have reported that human plasma can normally contain acrolein-protein adducts at 
concentrations of 30 to 50 µM [120]. Respiratory toxicity has been shown to occur at 
approximately 40 µM [121]. Additionally, Alzheimer’s patients have been found to have 
increased concentrations of acrolein-protein adducts in several brain regions at 10 µM 
[11]. Therefore, the concentrations of acrolein used in our study are achievable in vivo. 
We are the first to utilize RA-differentiated SH-SY5Y cells as a model for studying 
neurotoxicity induced by acrolein and neuroprotection by CDDO-Im against acrolein 
induced-oxidative damage.  These cells are classified as dopaminergic neurons because 
the RA differentiation ensures they have more developed neurotransmission capabilities 
including high levels of dopamine hydroxylase and tyrosine hydroxylase [37, 66, 122, 
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123]. Thus, these cells represent a widely used in vitro model for the study of human 
neurodegenerative disorders.  Given that CDDO-Im shows potency at nanomolar 
concentrations for induction of endogenous GSH that affords protection against acrolein-
induced cytotoxicity, it is likely that target of induction of endogenous GSH by CDDO-
Im may afford a protective influence against neurodegenerative diseases. 
In conclusion, this study demonstrates for the first time that cellular GSH can be 
potently induced by nanomolar concentrations of CDDO-Im in RA-differentiated SH-
SY5Y cells and afford protection against acrolein induced oxidative stress. We report that 
GSH, while not induction of AR or GST plays a predominant role in CDDO-Im mediated 
cytoprotection. These new findings may have implications for the development of novel 
therapies against reactive aldehyde-induced neurotoxicity. 
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